Gilead Sciences GILEAD Bond
GILD Stock | USD 64.78 0.55 0.84% |
Gilead Sciences holds a debt-to-equity ratio of 1.296. At present, Gilead Sciences' Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Short Term Debt is expected to grow to about 1.9 B, whereas Long Term Debt Total is forecasted to decline to about 19.7 B. Gilead Sciences' financial risk is the risk to Gilead Sciences stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Gilead Sciences' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Gilead Sciences' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Gilead Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Gilead Sciences' stakeholders.
For most companies, including Gilead Sciences, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Gilead Sciences the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 3.7175 | Book Value 14.009 | Operating Margin 0.3643 | Profit Margin 0.0177 | Return On Assets 0.1063 |
Gilead |
Given the importance of Gilead Sciences' capital structure, the first step in the capital decision process is for the management of Gilead Sciences to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Gilead Sciences to issue bonds at a reasonable cost.
Popular Name | Gilead Sciences GILEAD SCIENCES INC |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US3755581036 |
Bond Issue ISIN Code | US375558BT99 |
S&P Rating | Others |
Maturity Date | 1st of October 2050 |
Issuance Date | 30th of September 2020 |
Coupon | 2.8 % |
Gilead Sciences Outstanding Bond Obligations
GILEAD SCIENCES INC | US375558AX11 | Details | |
GILEAD SCIENCES INC | US375558AZ68 | Details | |
GILEAD SCIENCES INC | US375558AS26 | Details | |
GILEAD SCIENCES INC | US375558BK80 | Details | |
GILEAD SCIENCES INC | US375558BJ18 | Details | |
GILEAD SCIENCES INC | US375558BM47 | Details | |
GILEAD SCIENCES INC | US375558BA09 | Details | |
GILEAD SCIENCES INC | US375558BG78 | Details | |
GILEAD SCIENCES INC | US375558BF95 | Details | |
GILEAD SCIENCES INC | US375558BD48 | Details | |
GILEAD SCIENCES INC | US375558BY84 | Details | |
GILEAD SCIENCES INC | US375558BT99 | Details | |
GILEAD SCIENCES INC | US375558BS17 | Details | |
GILEAD SCIENCES INC | US375558BX02 | Details |
Understaning Gilead Sciences Use of Financial Leverage
Gilead Sciences financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Gilead Sciences's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Gilead Sciences assets, the company is considered highly leveraged. Understanding the composition and structure of overall Gilead Sciences debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Gilead Sciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Gilead Sciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 25 B | 26.2 B | |
Net Debt | 18.9 B | 19.8 B | |
Short Term Debt | 1.8 B | 1.9 B | |
Long Term Debt | 23.2 B | 12.2 B | |
Long Term Debt Total | 26.4 B | 19.7 B | |
Short and Long Term Debt | 1.8 B | 3.5 B | |
Net Debt To EBITDA | 1.62 | 0.94 | |
Debt To Equity | 1.10 | 1.15 | |
Interest Debt Per Share | 20.78 | 21.82 | |
Debt To Assets | 0.40 | 0.42 | |
Long Term Debt To Capitalization | 0.50 | 0.53 | |
Total Debt To Capitalization | 0.52 | 0.55 | |
Debt Equity Ratio | 1.10 | 1.15 | |
Debt Ratio | 0.40 | 0.42 | |
Cash Flow To Debt Ratio | 0.32 | 0.30 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Gilead Sciences Fundamentals Over Time. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3.02 | Earnings Share 0.36 | Revenue Per Share 22 | Quarterly Revenue Growth 0.053 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.